Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy

Phase 3

Terminated

• Conditions: Renal Cell Cancer, Recurrent; Renal Cell Carcinoma, Metastatic
• Interventions: Behavioral: Concomitant coaching

• Registration Number: NCT03013946
• Lead Sponsor: AIO-Studien-gGmbH

Brief Summary

The primary objective of the trial is to determine the effect of a 24-week concomitant coaching on patient reported outcomes of patients receiving standard treatment for mRCC with sunitinib or a combination of pembrolizumab + axitinib or avelumab + axitinib in first line therapy.

Detailed Description

The goal of our study is to define the benefit of proactive coaching in mRCC, when compared to a reactive approach, which is considered the standard of care.

Patients in the Coaching Arm A will be trained continuously at personal interactions of coach and patient (Face-to Face meetings as well as telephone contacts). The patient is educated on nature and severity of treatment emergent Adverse events (TEAE) of sunitinib or a combination of pembrolizumab + axitinib or avelumab + axitinib in first line therapy.

Quality of Life (QoL) is assessed during sunitinib treatment in both arms (Arm A Coaching and Arm B non Coaching).

Study Timeline

• Study First Submitted: 2016-12-14
• Study First Submitted QC: 2017-01-05
• Study First Posted: 2017-01-09
• Study Start: 2017-01-18
• Primary Completion: 2024-01-16
• Study Completion: 2024-01-16
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-12
• Last Update Posted: 2025-02-14

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 121

Inclusion Criteria

1. Written informed consent and any locally-required authorization (EU Data Privacy Directive in the EU) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations
2. Age ≥ 18 years at time of study entry
3. Advanced or metastatic renal cell carcinoma, not amendable to surgery with curative intent, rendering the patient eligible for Tyrosin Kinase Inhibitor (TKI) treatment with sunitinib
4. Intended first-line treatment with sunitinib
5. Documented progressive disease within 6 months prior to study inclusion
6. Patients with measurable disease (at least one uni-dimensionally measurable target lesion by CT-scan or MRI) according to modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1) as well as non-measurable disease are eligible.
7. Prior radiotherapy and surgery are allowed if completed 4 weeks (for minor surgery and palliative radiotherapy for bone pain: 2 weeks) prior to start of treatment and patient recovered from toxic effects.
8. Female subjects must either be of non-reproductive potential (ie, post-menopausal by history: ≥60 years old and no menses for ≥1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry.
9. Subject is willing to receive additional concomitant coaching and able to comply with the QoL/PRO (patient-reported outcome) assessments specified in the protocol for the duration of the study including scheduled visits, examinations and follow up.

Exclusion Criteria

1. Any other anti-cancer treatment aside of sunitinib for mRCC (except palliative radiotherapy)

2. Previous malignancy (other than mRCC) which either progresses or requires active treatment.

   Exceptions are: basal cell cancer of the skin, pre-invasive cancer of the cervix, T1a or T1b prostate carcinoma, or superficial bladder tumor [Ta, Tis and T1].

3. CNS metastases, unless local therapy has been completed for at least 3 month and patient does not require the use of steroids.

4. Chronic liver disease with Child-Pugh B or C score

5. Female subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control (failure rate of less than 1% per year)

6. Any condition that, in the opinion of the investigator, would interfere with evaluation of the concomitant coaching or QoL assessments or interpretation of patient safety or study results

7. Participation in another clinical study with an investigational product during the last 30 days before inclusion

8. Any previous treatment with a tyrosine kinase inhibitor for metastatic disease. Adjuvant or neoadjuvant therapy for localized disease is permitted, provided that relapse occurred at least 6 months after last exposure

9. Previous enrollment or randomization in the present study (does not include screening failure).

10. Involvement in the planning and/or conduct of the study (applies to both Pfizer staff and/or staff of sponsor and study site)

11. Patient who might be affiliated or otherwise dependent on the sponsor, site or the investigator

12. Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities [§ 40 Abs. 1 S. 3 Nr. 4 AMG].

13. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm A (Coaching)	Concomitant coaching	Concomitant coaching (24 weeks) Pro-active TEAE (Treatment emergent adverse events) management Cancer therapy according to Standard of Care (SOC) QoL assessments/ primary endpoint FKSI-15

Primary Outcome Measures

Name	Time	Method
QoL assessment during sunitinib treatment: questionnaire	24 weeks from randomization	Rate of responders to concomitant coaching assessed by the (Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI)) FKSI-15 questionnaire.

Secondary Outcome Measures

Name	Time	Method
progression-free survival (PFS)	up to 36 months from randomization	progression-free survival (PFS)
Patient adherence / treatment discontinuation due to Adverse drug reactions (ADRs) / Serious adverse events (SAEs):	24 weeks from randomization	% of patients with treatment discontinuation due to specific ADRs (e.g. hand-foot syndrome, diarrhea, stomatitis, fatigue, hypertension)
Assessment of comorbidities	at inclusion	Charlson Comorbidity Index (CCI)
Overall Survival (OS)	up to 36 months from randomization	Overall Survival (OS)
Treatment Emergent Adverse Events according to CTC 4.03:	24 weeks from randomization	* Frequency/incidence, severity, percentage reduction, time-to-event of ADRs, AEs and specific TEAEs (e.g. hand-foot syndrome, diarrhea, stomatitis, fatigue, hypertension); * change of grade 3/4 ADRs
Objective Response Rate (ORR) according to RECIST 1.1 criteria	up to one year from randomization	Objective Response Rate (ORR) according to RECIST 1.1 criteria
Duration of treatment (coaching and cancer treatment)	Coaching: up to 24 weeks from randomization / cancer treatment: up to 36 months from randomization	Duration of treatment (coaching and cancer treatment)
Rate of patients receiving treatment beyond progression	up to 36 months from randomization	Rate of patients receiving treatment beyond progression
dose density of sunitinib	24 weeks from randomization	dose density of sunitinib
Further cancer treatment	up to 36 months	Further cancer treatment
Time to first subsequent therapy (TFST)	up to 36 months	Time to first subsequent therapy (TFST)

Trial Locations

Locations (22)

Krankenhaus Barmherzige Brüder Regensburg; 🇩🇪 Regensburg, Bayern, Germany

Universitätsklinikum Frankfurt; 🇩🇪 Frankfurt am Main, Hessen, Germany

Universitätsmedizin Göttingen; 🇩🇪 Göttingen, Niedersachsen, Germany

Hämatologisch-Onkologische Praxis Stolberg; 🇩🇪 Stolberg, Nordrhein-Westfalen, Germany

Universitätsklinikum Essen (AöR); 🇩🇪 Essen, Nordrhein-Westphalen, Germany

Krankenhaus Barmherzige Brüder Trier; 🇩🇪 Trier, Rheinland-Pfalz, Germany

Universitätsklinikum Magdeburg A.ö.R.; 🇩🇪 Magdeburg, Sachsen-Anhalt, Germany

Urologische Arztpraxis Dr. Ralf Eckert; 🇩🇪 Wittenberg, Sachsen-Anhalt, Germany

Universitätsklinikum Schleswig-Holstein; 🇩🇪 Lübeck, Schleswig-Holstein, Germany

Klinikum St. Marien Amberg; 🇩🇪 Amberg, Germany

Onkologisches Versorgungszentrum; 🇩🇪 Berlin, Germany

Vivantes Klinikum Neukölln; 🇩🇪 Berlin, Germany

BAG Onkologische Gemeinschaftspraxis; 🇩🇪 Dresden, Germany

Gemeinschaftspraxis Dr. med. Johannes Mohm Dr. med. Gabriele Prange Krex Fachärzte für Innere Medizin Hämatologie und Internistische Onkologie; 🇩🇪 Dresden, Germany

MVZ für Hämato/Onkologie Essen gGmbH; 🇩🇪 Essen, Germany

MVZ Onkologische Kooperation Harz; 🇩🇪 Goslar, Germany

Medizinische Hochschule Hannover; 🇩🇪 Hannover, Germany

Tagesklinik Landshut Hämatologie, Onkologie Palliativmedizin; 🇩🇪 Landshut, Germany

Klinikum Nürnberg 5. Medizinische Klinik; 🇩🇪 Nürnberg, Germany

Wissenschaftskontor Nord GmbH & Co KG; 🇩🇪 Rostock, Germany

Onkologische Schwerpunktpraxis; 🇩🇪 Singen, Germany

MVZ Kloster Paradiese GbR/Onkologiezentrum Soest; 🇩🇪 Soest, Germany